Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business dayGet my quote

Renal cell carcinoma (kidney cancer): US-approved treatments and how Gulf families can access them

Creator: Reserve Meds
Published: 2026-10-17

A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Renal cell carcinoma: the short answer

The US FDA has approved five medicines on this page for renal cell carcinoma, each for specific patients. Five of them are on at least one Gulf register we checked, so ask your hospital about local supply first. Otherwise the hospital can request a named-patient import. Reserve Meds is a digital health company. We do not diagnose or prescribe.

US FDA-approved medicines on this page: Keytruda, Opdivo, Cabometyx, Lenvima and Welireg.
Gulf registration (checked 17 October 2026): see each medicine below.
Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital.
Price: Quote on request.

What is renal cell carcinoma?

Kidney cancer forms in the lining of tiny tubes inside the kidneys. Renal cell carcinoma is the most common type in adults. It becomes more likely with age. Risk factors include smoking, certain genetic conditions and long-term misuse of pain medicines.^[1]

There may be no symptoms at first. Signs can include blood in the urine, a lump in the abdomen, unexplained weight loss, ongoing pain in the side and loss of appetite.^[1]

Diagnosis uses blood, urine and imaging tests and sometimes a biopsy. Treatment can include surgery and, for advanced disease, immunotherapy and targeted therapy, often in combination. A US-approved tablet also treats kidney tumors linked to von Hippel-Lindau disease.^{[1, 2, 3]}

Renal cell carcinoma in the Gulf

Salmaniya Medical Complex in Bahrain documented 65 kidney cancer cases from 2014 to 2018, about 13 per year, with a mean age at diagnosis of 57.6 years. The authors cite GCC registry data reporting 4,078 renal cell carcinoma cases from 1998 to 2012.^[4]

US FDA-approved medicines for renal cell carcinoma

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

Keytruda (pembrolizumab)
FDA-approved for adults with advanced RCC as first-line treatment with axitinib or with lenvatinib, and as adjuvant treatment after surgery for RCC at intermediate-high or high risk of recurrence. It is given by intravenous infusion.^[2]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[5, 6]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Jordan, Lebanon, Iraq, Turkey, India, Pakistan
Opdivo (nivolumab)
FDA-approved for adults with advanced RCC, first-line with ipilimumab (intermediate or poor risk) or with cabozantinib, and after prior anti-angiogenic therapy. It is given by intravenous infusion.^[7]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[5, 6]}
Cabometyx (cabozantinib)
FDA-approved for patients with advanced RCC, alone or first-line with nivolumab. It is a tablet. It is also approved for some liver and thyroid cancers.^[8]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[5, 6]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, India
Lenvima (lenvatinib)
FDA-approved for adults with advanced RCC, first-line with pembrolizumab, and other combinations listed in the label. It is a capsule.^[9]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[5, 6]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, India
Welireg (belzutifan)
FDA-approved for adults with advanced RCC after a PD-1 or PD-L1 inhibitor and a VEGF-TKI, and adults with von Hippel-Lindau disease who need treatment for associated RCC and other tumors, as listed in the label. It is a tablet.^[3]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[5, 6]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, India, Pakistan

How families in the Gulf can access these medicines

If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks the medicine, and another brand of the same medicine may also be registered, but local supply is usually the fastest route and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.^{[10, 11]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

Who does what

Your treating specialist decides whether a medicine is right for the patient and writes the letter.
The hospital checks local supply, files any import request, and gives the treatment safely.
The national regulator decides whether to approve the import of a medicine that is not registered.
The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

A letter from the treating specialist with the diagnosis, past treatments and why the medicine is being considered
Reports that confirm the diagnosis, such as laboratory, genetic, imaging or pathology results, translated into English where needed
Recent clinic notes and a list of current medicines
For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for renal cell carcinoma

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Is there an FDA-approved treatment for renal cell carcinoma?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Keytruda, Opdivo, Cabometyx, Lenvima and Welireg. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Keytruda available in Saudi Arabia or the UAE?

Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. A listing in Abu Dhabi does not show federal UAE status.

How can a family in the Gulf get Keytruda?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

What is adjuvant treatment?

It is treatment given after surgery to lower the chance the cancer comes back. Keytruda's US label includes adjuvant treatment for RCC at intermediate-high or high risk after nephrectomy.

What is von Hippel-Lindau disease?

It is an inherited condition that causes tumors, including kidney tumors. Welireg's US label includes adults with VHL who need treatment for associated RCC and some other tumors.

Sources for the last two answers: ^[2] ^[3]

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.